^
    Back
    Association details:
    Biomarker:PCM1-JAK2 fusion
    Cancer:Chronic Myeloid Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Haematologica
    Title:

    Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

    Excerpt:
    Both patients with JAK2 rearrangements showed an overall reduction in JAK2 rearranged colonies (&x003C7;2 test; case 1, P<0.02; case 2, P<0.05). In case 1, complete eradication of PCM1-JAK2 positive colonies at 500 nM ruxolitinib was seen.
    DOI:
    https://dx.doi.org/10.3324%2Fhaematol.2012.067959